HCPCS Level II code Q5159 identifies the biosimilar denosumab product denosumab-dssb (ospomyv/xbryk) billed per 1 mg for injectable administration. As a biologic biosimilar to denosumab, this product is used in clinical settings where monoclonal antibody therapies are indicated; accurate coding matters for drug inventory, administration tracking, and payer reimbursement workflows nationwide. Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical and billing context, typical sites of service, and what to expect in payer coverage considerations. The publication outlines benchmarks and policy-relevant items typically tracked for biosimilar injectable products, highlights common billing modifiers and service-line implications (where available), and summarizes areas where clinicians and billing teams should confirm payer-specific rules and prior authorization requirements. Data not available in the input is noted where applicable. This national-level summary is intended to orient billing professionals, revenue integrity teams, and clinicians to the primary meaning and administrative implications of HCPCS Level II code Q5159.